Android app on Google Play

Wells Fargo Adds ViroPharma (VPHM) to Its Priority List

March 1, 2013 10:17 AM EST Send to a Friend
Get Alerts VPHM Hot Sheet
Price: $49.96 --0%

Rating Summary:
    7 Buy, 13 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 32 | Down: 19 | New: 39
Trade VPHM Now!
Join SI Premium – FREE
Wells Fargo today added ViroPharma Inc. (Nasdaq: VPHM) to its priority stock list, calling the stock its highest conviction mid-cap biotech idea.

Analysts said they have continued conviction that there is a significant discount between the stock's current valuation and the company's strong fundamentals.

"We believe that the revenues from the Cinryze franchise will continue to grow consistently based on the solid HAE demand metrics. Additionally, with no other companies yet pursuing an IV C1esterase for prophylaxis, the efficacy of subQ C1esterase inhibitors unproven and their potential convenience advantages over Cinryze likely modest, VPHM having the most promising subQ C1esterase anyway, and the general reticence of patients on effective orphan therapies to change, we believe concerns over post2015 Cinryze market share erosion are substantially overstated," wrote an analyst at the bank.




You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Wells Fargo

Add Your Comment